FDA OKS REVEFENACIN (YUPELRI) FOR COPD

Revefenacin, a long-acting muscarinic antagonist, is the first once-daily nebulized bronchodilator approved for chronic obstructive pulmonary disease (COPD) in the US. FDA Approvals

medscape.com (Date:11/10/2018 14:06) Read full article >>

Related News about "FDA OKs Revefenacin (Yupelri) for COPD" news from other sites: (news similarity rate is shown on left.)

36%
Cruise proves breath of fresh air for COPD sufferers It's the 23rd annual Fresh Air Day cruise aboard the tourist boat, a treasured event equivalent to a jamboree for Granite Staters in their late 50s thru mid 90s who have chronic obstructive pulmonary .. unionleader.com >>
25%
Those in COPD group give, get support Resources for COPD sufferers and those who suspect it are available at www.breathenh.org, and from the National Heart, Lung, and Blood Institute at COPD.nhlbi.nih.gov... unionleader.com >>
41%
Testosterone replacement therapy may slow the progression of COPD Testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease, according to new research... ScienceDaily.com >>
39%
Autoimmunity plays role in development of COPD Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a new study that analyzed human genome information... ScienceDaily.com >>
31%
More than 40 percent of women with asthma may develop COPD, but risk may be reduced More than four in 10 women with asthma may go on to develop chronic obstructive pulmonary disease (COPD), according to a study conducted in Ontario, Canada... ScienceDaily.com >>